HPMPC (Cidofovir) Peripheral CMV Retinitis Trial Protocol

Inclusion Criteria Concurrent Medication: Allowed: Oral trimethoprim/sulfamethoxazole. Aerosolized pentamidine. Dapsone. Fluconazole. Ketoconazole. Itraconazole. Rifabutin. Filgrastim (G-CSF). Antiretroviral agents. Patients must have: AIDS by CDC criteria. CMV retinitis as determined by a SOCA-certified ophthalmologist, with lesion size, location, and severity as specified in the Disease Status field. Prior Medication: Allowed: Prophylaxis with anti-CMV agents. Exclusion Criteria Concurrent Medication: Excluded: Ongoing therapy for CMV disease with ganciclovir, foscarnet, CMV hyperimmune immunoglobulin, or other investigational agents with anti-CMV activity. Therapy with nephrotoxic drugs, including amphotericin B, aminoglycoside antibiotics, vidarabine, and intravenous pentamidine. Patients with the following prior conditions are excluded: History of renal disease or renal dialysis. History of clinically significant cardiac disease, including symptoms of ischemia, congestive heart failure, or arrhythmia. History of clinically significant probenecid allergy. Prior Medication: Excluded: Prior therapy for CMV disease with ganciclovir, foscarnet, CMV hyperimmune immunoglobulin, or other investigational agents with anti-CMV activity. Therapy with nephrotoxic drugs within the past 7 days, including amphotericin B, aminoglycoside antibiotics, vidarabine, and intravenous pentamidine. Drug or alcohol abuse sufficient to hinder compliance with study.